報價延遲最少15分鐘:2025/01/21 08:38 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.83 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.01/-0.60
|
|
企業價值
175.75M
|
| 資產負債 |
|
每股賬面淨值
1.88
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
23.35M
|
|
每股收益
1.64
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/21 08:38 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment. |